RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Article 2009 en
Authors
KL
KangAe Lee
HZ
Huafeng Zhang
DQ
David Z. Qian
Abstract
1 min read
HIF-1 is a heterodimeric transcription factor that mediates adaptive responses to hypoxia and plays critical roles in cancer progression. Using a cell-based screening assay we have identified acriflavine as a drug that binds directly to HIF-1α and HIF-2α and inhibits HIF-1 dimerization and transcriptional activity. Pretreatment of mice bearing prostate cancer xenografts with acriflavine prevented tumor growth and treatment of mice bearing established tumors resulted in growth arrest. Acriflavine treatment inhibited intratumoral expression of angiogenic cytokines, mobilization of angiogenic cells into peripheral blood, and tumor vascularization. These results provide proof of principle that small molecules can inhibit dimerization of HIF-1 and have potent inhibitory effects on tumor growth and vascularization.
Rajani Ravi, Bijoyesh Mookerjee, Zaver M. Bhujwalla, Thomas R. Sutter, Dmitri Artemov, Qinwen Zeng, Larry E. Dillehay, Ashima Madan, Gregg L. Friedman, Atul Bedi
Huafeng Zhang, David Z. Qian, Yee Sun Tan, KangAe Lee, Ping Gao, Yunzhao R. Ren, Sergio Rey, Hans J. Hammers, Daniel Chang, Роберто Пили, Chi V. Dang, Jun O. Liu, Gregg L. Friedman
Discussion(0)
No comments yet. Be the first to comment.